Topaz vs. Evoque: New Head-to-Head Study for TTVR Devices Now Underway

Topaz vs. Evoque: New head-to-head study for TTVR devices now underway

Researchers are comparing the new-look Topaz TTVR system from TRiCares with the FDA-approved Evoque TTVR system from Edwards Lifesciences.

TRICURE US Pivotal Study Begins for TriCares’ Topaz TTVR System

July 10, 2026—TriCares SAS announced that the first patient has been enrolled and treated in the TRICURE United States investigation device exemption (IDE) pivotal study, which is evaluating the company’s Topaz transcatheter tricuspid valve replacement (TTVR) system in the treatment of tricuspid regurgitation (TR). The randomized controlled study is actively enrolling patients in a head-to-head comparison of its investigational TTVR system versu…

First patient joins randomised trial comparing TTVR systems

Topaz TRiCares has announced that the first patient has been enrolled and treated in the TRICURE US IDE pivotal study, evaluating Topaz, its transcatheter tricuspid valve replacement (TTVR) system. This enrolment marks the first randomised controlled study to actively enrol patients in a head-to-head comparison of an investigational TTVR system versus the commercially available Evoque TTVR system (Edwards Lifesciences). The US pivotal study init…